Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The head space of 2C-T-2 is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
The visual geometry of 2C-T-2 can be described as somewhat similar in appearance to that of ayahuasca, psilocin, and 4-AcO-DMT, with mystical and shamanic undertones which combine with synthetic digital undertones reminiscent of LSD or 2C-E. 2C-T-2's geometry can be comprehensively described as intricate in complexity, abstract in form, organic but somewhat synthetic in style, structured in organization, brightly lit and multicoloured in scheme, glossy in shading, rounded in edges, large in size, fast in speed, smooth in motion, mostly angular in corners, immersive in depth and consistent in intensity. The visuals have a contradictory 'natural' and 'synthetic' feel to them which is reminiscent of DOC or 2C-P. Higher dosages are more likely to result in states of Level 8B visual geometry, but may also lead into Level 8A visual geometry.
2C-T-2 produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.
The auditory effects of 2C-T-2 are more common in their occurrence than many more commonly used psychedelics.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-2 is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, though some individuals may use it more frequently than intended.
2C-T-2 is not physically addicting. Withdrawal effects following discontinuation have not been reported.
The exact toxic dosage is unknown. The toxicity and long-term health effects of recreational 2C-T-2 use have not been studied in any scientific context.
In vitro studies have demonstrated potential neurotoxicity to serotonergic and dopaminergic neurons, though the concentrations used (>50 μM) are unlikely to translate to recreational use of the compound.
As with other serotonergic psychedelics, 2C-T-2 may trigger latent psychological and mental conditions in predisposed individuals. Those with a family history of schizophrenia or early onset mental illness should exercise extreme caution. Severe intoxication has been associated with intense hallucinations, agitation, aggression, violence, and dysphoria.
Seizures have been reported as part of severe intoxication with 2C series drugs. Individuals with a seizure or convulsive disorder may be at higher risk when taking 2C-T-2.
2C-T-2 was first synthesized by Alexander Shulgin in 1981. That same year, Shulgin discovered its psychedelic properties through self-experimentation, establishing the compound's activity in humans.
EU Council Decision 2003/847/JHA (December 6, 2003) - Member states required to implement control measures and criminal penalties for 2C-T-2, 2C-I, 2C-T-7, and TMA-2
Listed as a controlled substance alongside other phenethylamines including 2C-B and 2C-I.
Prohibited under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are illegal.
Controlled as of February 18, 2014. Listed on Portaria SVS/MS nº 344, making possession, production, and sale illegal.
Added to the list of controlled substances as of October 2015.
Added to Schedule I in February 2011 alongside several other phenethylamines and synthetic cannabinoids.
Listed in Anlage I (Schedule I) of the Betäubungsmittelgesetz (Narcotics Act) since October 1998. Represents the highest level of control; manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
Controlled under the Pharmaceutical Affairs Law. Possession and sale are illegal.
The Netherlands was the first country to ban 2C-T-2, classifying it as a hard drug under List I of the Opium Law in April 1999. Unlicensed manufacture, sale, import, trade, and possession can be prosecuted.
Added to Grade 2 (equivalent to Schedule II under the 1971 UN Convention on Psychotropic Substances) in October 2009.
Specifically named as a controlled substance under Verzeichnis D of the Swiss narcotics legislation.
Federally scheduled under SEC. 1152 of the Food and Drug Administration Safety and Innovation Act of 2012 (S.3187), signed into law in July 2012. Possession, manufacture, and import are illegal. Additional state-level controls exist in Alabama (February 2013), Louisiana (June 2013), Oklahoma (May 2011), Pennsylvania, and Vermont (July 2012).
Classified as a prohibited substance under the Poisons Standard since 2005. Schedule 9 substances are those which may be abused or misused and are prohibited except for approved medical or scientific research, analytical, teaching, or training purposes with government authorization.
Added to the list of controlled psychotropic substances on November 8, 2004.
Controlled under the Controlled Drugs and Substances Act as of October 31, 2016. Classified as a derivative of 2,5-dimethoxyphenethylamine.
Added to Category B of the controlled substances list on August 23, 2003.
Classified as a narcotic substance under Finnish drug control legislation.
Added to Tabella I (the list of prohibited plants and substances) by Ministry of Health statement on January 11, 2005.
Listed as a Schedule I controlled substance under national drug legislation.
Law enacted in January 2005 to control 2C-T-2, 2C-I, 2C-T-7, and TMA-2.
First regulated on April 1, 1999 under the Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:58), making sale and possession illegal. Subsequently added to Schedule I of the Narcotic Drugs Punishments Act on March 16, 2004, as published in MPA regulation LVFS 2004:3.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 through the phenethylamine catch-all clause. All compounds featured in PiHKAL are prohibited. Class A carries the most severe penalties for possession, manufacture, and import.
14 sources cited
